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0163-7258/© 2016 The Authors. Published by Elseviera b s t r a c ta r t i c l e i n f oAvailable online 1 July 2016 Osteoprotegerin (tnfsf11b, OPG) is a solublemember of the TNF superfamily originally described as an important
regulator of osteoclastogenesis almost 20 years ago. OPG is a heparin-binding secreted glycoprotein that exists as
a 55–62 kDa monomer or a 110–120 kDa disulphide-linked homodimer. Acting as a soluble decoy receptor for
RANKL, OPG actively regulates RANK signalling, and thereby osteoclastogenesis. OPG has subsequently been
shown to also be a decoy receptor TNF related apoptosis inducing-ligand (tnfsf10, TRAIL, Apo2L). TRAIL is a
type II transmembrane protein that is widely expressed in a variety of human tissues, including the spleen,
lung, and prostate. Through binding to TRAIL, OPG can inhibit TRAIL-induced apoptosis of cancer cells. More
recently, OPG has been demonstrated to be secreted by, and inﬂuence, vascular smooth muscle cells phenotype
particularly related to vascular calciﬁcation and pulmonary vascular remodelling. In pulmonary artery smooth
muscle cell (PASMC) suppression of BMP, induction of 5-HT and IL-1 signalling have been shown to stimulate
the release of OPG in vitro, which causes cell migration and proliferation. Patients with idiopathic PAH (IPAH)
demonstrate increased circulating and tissue levels of OPG, and circulating serum levels predict survival. In
pre-clinical models, OPG levels correlate with disease severity. Since OPG is a naturally circulating protein, we
are investigating the potential of novel biologic antibody therapies to rescue PAH phenotype in disease models.
Further pre-clinical andmechanistic data are forthcoming, but we believe current published data identify OPG as
an exciting and novel therapeutic target in PAH.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Since its discovery nearly 20 years ago, there have been signiﬁcant
advances in our understanding of the role of osteoprotegerin in health
and disease. Osteoprotegerin, meaning “to protect bone,”was originally
puriﬁed from human ﬁbroblast conditionedmedia and described as the
osteoclastogenesis inhibitory factor (OCIF) by Tsuda et al. (1997)
because of its ability to inhibit bone reabsorption (Tsuda et al., 1997).
Within the same year, Simonet et al. identiﬁed OPG as an important
regulator of bone density after transgenic mice overexpressing OPG
developed osteopetrosis and a decrease in osteoclast number (Simonet
et al., 1997). Analysis of a foetal rat intestinal library revealed a 401-
amino-acid-long, secreted cytokine with an N-terminus analogous to
TNF receptor superfamily members (Simonet et al., 1997). We now
know that OPG is a heparin-binding secreted glycoprotein belonging to
the TNF receptor superfamily that exists as either a 55–62 kDamonomer
or a 110–120 kDa disulphide-linked homodimer (Simonet et al., 1997;
Zauli et al., 2007).
OPG contains a 21-amino-acid long signal peptide that is cleaved to
generate themature, 380-amino-acid-long form (Zauli et al., 2007). The
OPG protein consists of seven structural domains; the function of all but
one of these domains has been determined. Domains 1–4 are cysteine
rich and share structural similarities with the TNF receptor extracellular
domains, and are sufﬁcient to abolish osteoclastogenesis. Domains 5
and 6 contain death domains, which share similarities with both the
Fas and TRAIL death receptors. Domain 7 consists of 50 amino acids
and contains the cys-400 residue that is essential for disulphide bond
formation and dimerisation of OPG (Yamaguchi et al., 1998). Domain
7 may also play an important role in regulating the release and activity
of OPG (Zauli et al., 2007).
2. The osteoprotegerin/receptor activator of nuclear factor κ B
ligand/receptor activator of nuclear factor κ B axis in bone biology
The osteoprotegerin (OPG), receptor activator of nuclear factor κ B
ligand (RANKL), receptor activator of nuclear factor κ B (RANK) axis
plays an important role in bone remodelling and is critical for regulating
bone density. OPG acts as a decoy receptor for RANKL to inhibit
osteoclastogensis (Yasuda et al., 1998; Vitovski et al., 2007). Bone is
continuously renewed through reabsorption at the trabeculae by osteo-
clasts, and new bone deposition by osteoblasts (Hofbauer & Schoppet,
2004; Boyce & Xing, 2007). Osteoclastogenesis requires binding of
RANKL, a type 2 homotrimeric transmembrane protein expressed on
mature osteoblasts, to its receptor, RANK, a type 1 homotrimeric
transmembrane protein expressed on osteoclast precursor cells
(Hofbauer & Schoppet, 2004; Boyce & Xing, 2007; Vitovski et al., 2007)
(Fig. 1). Upon formation, this receptor ligand complex induces osteoclast
formation, activation, and survival via NF-kB through recruitment of the
adaptor protein, tumor necrosis factor receptor associated factor 6
(TRAF6) (Boyce & Xing, 2007) to prevent precursor differentiation into
macrophages (Hofbauer & Schoppet, 2004; Boyce & Xing, 2007;Fig. 1.Model of OPG regulation of bone remodelling and TRAIL-induced apoptosis. OPG binds to R
regulate osteoclastogenesis. OPG can also bind to TRAIL and inhibit TRAIL binding to TRAIL r
apoptosis.Vitovski et al., 2007). NF-kB then translocates to the nucleus to induce
c-Fos expression, which subsequently results in osteoclastogenic gene
transcription. OPG, secreted from osteoblasts, acts as a decoy receptor
for RANKL, preventing the RANKL–RANK binding, osteoclast activation,
and subsequent bone reabsorption (Hofbauer & Schoppet, 2004;
Vitovski et al., 2007). Post-natal OPG is critical for the maintenance of
bone density and disruptedOPGexpression in vivo results in the develop-
ment of bone disorders (Bucay et al., 1998). OPG knockout mice exhibit
osteoporosis due to excessive bone reabsorption (Bucay et al., 1998),
and conversely, elevated OPG levels or inactive RANKL result in
osteopetrosis due to reduced bone reabsorption (Simonet et al., 1997;
Vitovski et al., 2007). In order to protect against excessive bone reabsorp-
tion, OPG mRNA is up-regulated during the normal process of bone for-
mation (Tanaka et al., 2011). The critical role for the regulation of OPG
has been highlighted by genetic studies showing that mutations in OPG,
that affect expression levels, have been associated with juvenile Paget's
disease (Whyte et al., 2002).
3. Osteoprotegerin and tumor necrosis factor (TNF)-related
apoptosis-inducing ligand in tumour cell biology
As well as its role in bone biology, OPG also plays an important role
in tumour cell biology as a decoy receptor for TRAIL (Emery et al., 1998).
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL,
Apo2L) is a type II transmembrane protein that is widely expressed in
a variety of human tissues, including the spleen, lung, and prostate. In
humans, TRAIL has four transmembrane receptors: death receptor 4
(DR4, TRAIL-R1), DR5 (TRAIL-R2), decoy receptor 1 (DcR1, TRAIL-R3),
DcR2 (TRAIL-R4), and the ﬁfth, OPG. By binding to TRAIL, OPG has
been shown to inhibit TRAIL-induced apoptosis of Jurkat cells, and
TRAIL also represses OPG inhibition of osteoclastogenesis (Emery
et al., 1998). Through interaction with TRAIL, OPG was also found to in-
hibit TRAIL-induced apoptosis of ovarian cancer cells (Cross et al., 2006),
a process that occurs in an αvβ3 integrin and αvβ5 integrin-dependent
manner (Lane et al., 2012, 2013). OPG has also been reported to prevent
TRAIL-induced apoptosis of human microvascular endothelial cells
(HMVECs), a process also requiring αvβ3 (Pritzker et al., 2004) (Fig. 1).
Along with cancer cell survival, OPG has also been implicated in
angiogenesis, a process required for the maintenance, development,
and progression of tumours (Cross et al., 2006). OPG expression was
identiﬁed in the endothelium of malignant colorectal, breast, and meta-
static cancer tumours, but not in the endothelium of benign tumours or
normal tissue. OPG induces human dermal microvascular endothelial
cells (HuDMECs) to form cord-like capillary structure (Cross et al.,
2006) and induces vessel-formation in vivo via heparin binding
(McGonigle et al., 2008). More recently, work undertaken by
Benslimane–Ahmim and colleagues has shown that OPG induces the
migration and differentiation of endothelial colony-forming cells into
cord-like structures, promotesﬁbroblast growth factor-2 (FGF2)-induced
neo-angiogenesis in vivo, and increases endothelial colony-forming cell
adhesion to ﬁbronectin in vitro (Benslimane-Ahmim et al., 2013).ANKL expressed by stromal cells to prevent RANK–RANKL binding on pre-osteoclasts to
eceptors expressed on tumour cells. In doing so, OPG can protect against TRAIL-induced
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OPGhas beenwell described for its critical role bone biology but also
more recently in vascular biology. OPG is known to bewidely expressed
in a variety of tissues, including the human heart, kidney, placenta, and
lung (Simonet et al., 1997). A variety of cells express and secrete OPG,
including bone marrow stromal cells and cells belonging to the
osteoblastic cell lineage, B cells, megakaryocytes, platelets, vascular
endothelial cells, and vascular smooth muscle cells (Collin-Osdoby
et al., 2001; Collin-Osdoby, 2004; Olesen et al., 2005; Li et al., 2007;
Zauli et al., 2009; Condliffe et al., 2012). OPG has subsequently been im-
plicated in a variety of processes and diseases, including atherosclerosis,
vascular calciﬁcation, angiogenesis, and hypertension.
The development of calciﬁed arteries alongside osteoporosis in
OPG−/− mice ﬁrst revealed a role for OPG in vascular biology, and
accumulating evidence supports a protective role for OPG against
calciﬁcation (Bucay et al., 1998). OPGwas also shown to have protective
role in the progression and calciﬁcation of advanced atherosclerotic
lesions in the innominate arteries of Apolipoprotein E (ApoE)−/−
mice, in so much that aged mice double deﬁcient for ApoE and OPG
developed larger and more complex atherosclerotic lesions (Bennett
et al., 2006). Corollary, OPG treatment reduced vascular smoothmuscle
cell calciﬁcation in vitro, and subsequently, restoration of OPG reverses
experimental calciﬁcation in pre-clinical models (Schoppet et al.,
2011). High concentrations of calciumwhich induce calciﬁcation of vas-
cular smoothmuscle cells have also found to induce OPGmRNA expres-
sion in healthy vascular smooth muscles cells (Schoppet et al., 2011).
There is, however, some controversy surrounding the role of OPG in vas-
cular calciﬁcation. For example, concentrations of OPG equivalent to
those measured in coronary artery disease (CAD) and chronic kidney
disease (CKD) patient serum appear to have no measurable effect
against calciﬁcation (Schoppet et al., 2011). Olesen et al. (2012) report-
ed that OPG had no effect on vascular smooth muscle cells calciﬁcation.
The role of OPG in vascular calciﬁcation in disease still remains elusive.
5. Osteoprotegerin and vascular cell phenotype
There is now accumulating evidence that OPG plays an even wider
role in vascular biology. OPG induces the proliferation of vascular endo-
thelial cells from a variety of vascular beds including HuDMEC and
HUVEC (Cross et al., 2006), mediated through αvβ3 and αvβ5 integrins
(Kobayashi-Sakamoto et al., 2008). OPG-induced HuDMECs and
HUVECs proliferation has been shown to be mediated via a TRAIL-
independent signalling mechanism (Cross et al., 2006). However,
there are contradictions in the literature regarding the sensitivity of
HuDMECs and HUVECs to TRAIL and there have been reports in the lit-
erature that show TRAIL can alter HUVEC and HuDMEC phenotype
(Pritzker et al., 2004; Secchiero et al., 2004). In VSMCs, OPG has also
been shown to induce the survival of serum-deprived aortic SMCs
(Bennett et al., 2006), and the proliferation andmigration of pulmonary
artery SMC (Lawrie et al., 2008). Intriguingly, a microarray comparison
study of early and late passage VSMCs identiﬁed OPG to be one of the
most differentially expressed genes in senescence (Burton et al.,
2009), providing evidence linking OPG expression with vascular cell
phenotype.
OPG also binds to syndecan-1 (SDC-1) (Mosheimer et al., 2005;
Baud'huin et al., 2013), and the OPG–SDC-1 interaction has been
found to be important in monocyte migration (Mosheimer et al.,
2004) and may therefore inﬂuence vascular inﬂammation.
6. Osteoprotegerin in cardiovascular disease
OPG has been implicated as a potential mediator and biomarker in a
variety of cardiovascular diseases, particularly cardiometabolic condi-
tions (Pérez de Ciriza et al., 2015) and pulmonary hypertension
(Lawrie et al., 2008; Condliffe et al., 2012). In a recent patient study,hypertensive patients were shown to have elevated OPG levels com-
pared to control patients (Stępień et al., 2011). Elevated OPG levels
have also been observed within pericardium of malignant and non-
malignant pericardial effusion (Karatolios et al., 2012), and there is
also a positive correlation between the severity of peripheral artery dis-
ease (PAD) and plasma values of OPG (Ziegler et al., 2005). Expression
of OPG and its ligand, RANKL, have been observedwithin the failingmyo-
cardium, and OPG, RANKL, and RANK are all up-regulated in experimen-
tal and clinical heart failure. Patients with severe aortic stenosis exhibit
elevated systemic OPG expression andOPG, RANKL, and RANKmRNA ex-
pression is increased within ischemic areas of the left ventricle (Ueland
et al., 2012). OPG plasma levels are also a predictor of asymptomatic cor-
onary artery disease in type-2 diabetic patients andOPGplasma levels are
also signiﬁcantly higher in patients with systemic hypertension, de-
creased kidney function, and type 1 diabetic patients with nephropathy
and signs of cardiovascular disease (Ueland et al., 2004; Avignon et al.,
2005; Ueland et al., 2005; Rasmussen et al., 2006).
Although increased expression of OPG has been associated with
cardiovascular disease, OPG is actually thought to play an important
atheroprotective role as described above. Interestingly, pre-clinical
bone marrow transplantation experiments from mice suggest both
vessel wall-derived and bone marrow-derived OPG as sufﬁcient to re-
duce both atherosclerotic lesion size and calciﬁcation in the innominate
artery (Callegari et al., 2013). However, aswith the literature describing
the role OPG plays in calciﬁcation, there are conﬂicting reports regard-
ing the role of OPG in atherosclerosis. High-fat diet fed LDLR−/−mice
show a reduction in calciﬁcation after treatment with the recombinant
OPG–Fc protein, a synthesized version of OPG; however, there was no
effect on atherosclerotic lesion size (Morony et al., 2008). OPG has
been identiﬁed as a potentialmarker of atherosclerosis, as plasma levels
of OPG increase with increasing severity of atherosclerosis (Hosbond
et al., 2012; Kim et al., 2013). However, OPGmay also be amarker of dis-
ease onset as LDLR−/− mice have increased OPG levels upon disease
onset, which did not increase with disease progression (Morony et al.,
2008). This may not be the case in atherosclerosis patients; however,
it is clear from the currently available literature that further studies
are required ifwe are to fully elucidate the role of OPG in atherosclerosis
and cardiovascular disease.
7. Osteoprotegerin in pulmonary arterial hypertension
More recently, OPG has been implicated as a potential mediator in
the pathogenesis of PAH (Lawrie et al., 2008). Pulmonary arterial hyper-
tension (PAH) is a fatal lung disease characterised by progressive
pulmonary vascular remodelling, a key component of which is the
proliferation and migration of pulmonary arterial smooth muscle cells
(PASMCs). PAH is deﬁned as pre-capillary pulmonary hypertension
and is diagnosed by right heart catheterisation as an mean pulmonary
artery pressure of greater than or equal to 25 mm Hg, a pulmonary
arterial wedge pressure of less than 15mmHg, and a pulmonary vascular
resistance (PVR) of greater than 240 dynes.s.cm−5 (3 Woods Units
(mm Hg/l.min)) (Hoeper et al., 2013). Pathologically, PAH is
characterised by sustained vasoconstriction and the obliteration of the
small pulmonary arteries and arterioles through medial hypertrophy,
muscularisation, intimal ﬁbrosis, and plexiform lesion formation (Tuder
et al., 2013). Although the exact cause of PAH is currently unknown,
endothelial dysfunction and pulmonary artery endothelial cell (PA-EC)
apoptosis is thought to be an important early insult in disease pathogen-
esis. Subsequent pulmonary arterial smoothmuscle cell (PASMC), PA-EC,
andﬁbroblast proliferation andmigrationwithin themedia of the pulmo-
nary artery are then thought to drive the pulmonary vascular remodelling
process (Tuder et al., 2013).
OPG is regulated by BMP signalling, serotonin, and interleukins,
predominantly IL-1, which are important pathways implicated in the
pathogenesis of PAH (Lawrie et al., 2008) (Fig. 2A). Immunohistochem-
ical analysis of human lungs from patients with idiopathic PAH (IPAH)
Fig. 2. Proposedmodel for OPG signalling events driving PAH pathogenesis. (A)Multiple stimuli including 5-HT, inﬂammation and reducedBMPR2 stimulate the expression and release ofOPG
causing an increase in intracellular kinase signalling leading to the activation of multiple genes associated with PAH. This induces a pro-survival, migratory, and proliferative phenotype
resulting promoting pulmonary vascular remodelling and PAH. (B) Inhibition of OPG reduces kinase expression and normalises the expression of the altered PAH-associated gene
expression to reduce the anti-apoptotic, pro-proliferative phenotype and induce reverse pulmonary vascular remodelling to normalise pulmonary vascular resistance and PAH. The
effect of OPG on TRAIL expression is unknown but unpublished research suggests additional links other than direct protein–protein interaction.
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lesions, and patients with IPAH also have increased serum levels of
OPG, which correlate with prognostic markers and survival
(Condliffe et al., 2012). PASMC isolated from patients with heritable
PAH (hPAH) known to be harbouring BMPR2 mutations have in-
creased expression of OPG, and the OPG-binding partners, TRAIL
and RANKL, compared to cells from controls (Lawrie et al., 2008;
Hameed et al., 2012). Normal, human PA-SMCs transfected with
BMPR2 short interfering RNA (siRNA, to mimic the heterozygous
loss of function BMPR2 mutation) demonstrated increased OPG re-
lease. Normal PASMC treated with 5HT and IL-1 also demonstrated
a dose-dependent increase in OPG release (Lawrie et al., 2008). Func-
tional studies have demonstrated that recombinant OPG induces
both the proliferation andmigration of PASMCs in vitro, in a dose-de-
pendent manner suggesting that OPG may be a key downstreamme-
diatory of disease pathogenesis (Fig. 2A).8. Therapeutic potential of blocking osteoprotegerin for the
treatment of pulmonary arterial hypertension
PAH describes a group of rapidly progressive conditions that share a
common diagnosis of increased blood pressure in the lungs that over
time the increased pressure causes heart failure. Pathologically the
disease is driven by progressive pulmonary vascular remodelling that
comprises a combination of sustained vasoconstriction and the oblitera-
tion of small pulmonary arteries through a process of cellular prolifera-
tion, intimal ﬁbrosis, and the formation of angio-proliferative
(plexiform) lesions (Tuder et al., 2013). Current treatments target
vasoconstriction via the prostacyclin, endothelin, or nitric oxide pathways
(Humbert et al., 2014). These drugs do little to address the underlying
proliferative vascular disease and there remains no curative pharmaco-
logical treatment for PAH, with the 3 and 5 year survival for PAH in its
idiopathic reported to be as low at 38% and 17%, respectively (Hurdman
et al., 2012). We have described above a potential key role that OPG,
which is found to be up-regulated within remodelled pulmonary arteries
from patients with PAH, is regulated by multiple pathways important in
PAH pathogenesis, and stimulates PASMC proliferation and migration
and plays in the pathogenesis of PAH. Given this proposed active role in
disease, we hypothesise that OPG is therefore a novel drug target. Since
OPG is a naturally secreted protein and is already known to interact
with several other proteins, we propose the best approach for targeting
OPG to be a monoclonal anti-OPG antibody (Fig. 2B). This is an avenue
that we are currently exploring with further pre-clinical studies currently
underway.9. Limitations of osteoprotegerin as a therapeutic target
Despite this promise, aswithmost therapeutic approaches, there are
risks associated with the inhibition of OPG. Theoretically, blockade or
inhibition of OPG may increase the availability of both RANKL and
TRAIL. The most obvious risk associated with this being osteoporosis,
or increased fracture risk due to the excess of RANKL–RANK-mediated
bone reabsorption. Indeed the use of a recombinant form of OPG has
previously been investigated as a therapeutic strategy to inhibit
RANKL demonstrated promising early-phase promise in clinical trials
(Bekker et al., 2001; Body et al., 2003); however, the emergence of
denosumab (Bekker et al., 2001), a human anti-RANKL monoclonal
antibody, superseded the development of recombinant OPG. However,
these detrimental effects on bone can likely be tolerated in the context
of PAH where life expectancy is substantially shortened and may be
treated with other therapeutic approached. Furthermore, better
understanding of the mechanism of action for OPG in PAHmay identify
a therapeutic approach to inhibit or block OPG while minimizing the
impact on bone biology.
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